A Randomized, Open-label, Interventional, Real-world Study to Compare the Efficacy and Safety of QL0605 Administered at Different Timepoints After Chemotherapy.
Latest Information Update: 03 Oct 2024
Price :
$35 *
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Adverse reactions
- Sponsors Qilu Pharmaceutical
- 03 Oct 2024 New trial record